Intensity Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

INTENSITY THERAPEUTICS (INTT) filed an 8-K for shareholder vote matters on Oct 22.

AI Summary

Intensity Therapeutics, Inc. filed an 8-K on October 23, 2025, reporting on a submission of matters to a vote of security holders that occurred on October 22, 2025. The company, incorporated in Delaware, is involved in biological products.

Why It Matters

This filing indicates a significant corporate event involving shareholder decisions, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: low — The filing is a standard procedural report on a shareholder vote and does not disclose new financial risks or operational changes.

Key Players & Entities

• INTENSITY THERAPEUTICS, INC. (company) — Registrant
• October 22, 2025 (date) — Date of earliest event reported
• October 23, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto

Filing Documents

• intensity-20251022.htm (8-K) — 29KB
• 0001567264-25-000096.txt ( ) — 150KB
• intensity-20251022.xsd (EX-101.SCH) — 2KB
• intensity-20251022_lab.xml (EX-101.LAB) — 23KB
• intensity-20251022_pre.xml (EX-101.PRE) — 13KB
• intensity-20251022_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 22, 2025, Intensity Therapeutics, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting") via live webcast. At the Special Meeting, 22,869,562 shares of common stock, or approximately 46.61% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person, representing a quorum. At the Special Meeting, the stockholders of the Company voted as set forth below on two proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 9, 2025. The final voting results for each matter submitted to a vote of the Company's stockholders are as follows: Proposal 1. Reverse Stock Split. The approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Amended and Restated Certificate of Incorporation"), to effect a reverse stock split of the Company's common stock by a ratio of not less than one-for-five and not more than one-for-thirty (the "Reverse Stock Split"), with the exact ratio to be set within this range by the board of directors in its sole discretion (without reducing the authorized number of shares of common stock) and with the board of directors able to elect to abandon such proposed amendment and not effect the Reverse Stock Split authorized by the Company's stockholders in its sole discretion. For Against Abstain 18,333,570 4,508,502 27,490 Proposal 2. Adjournment. The approval of the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of Proposal 1. For Against Abstain 18,869,741 3,893,779 106,042

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 23, 2025 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR